CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
The purpose of the study is to determine, long term, how well the drug, cemiplimab, works in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
Cutaneous Squamous Cell Carcinoma, CSCC
1. ≥18 years of age
2. Eligible for treatment with and prescribed cemiplimab for advanced CSCC in accordance with approved prescribing information
Healthy Volunteers Needed
Duration of Participation
Call our Dermatology clinical trials recruiter at 503-418-9386 or email email@example.com